News

Thelin will be withdrawn in regions where it is approved – the European Union, Canada and Australia, and the clinical studies of the drug will also be discontinued

The revised dosing recommendation extends the same dosing already approved for treatment-naive patients – Prezista, co-administered with ritonavir in combination with other antiretroviral agents and with food, once-daily

Actis will sell its 63% holding in Paras Pharma to RB. Reportedly, Sequoia Capital and the remaining shareholders, including Paras founder Girish Patel and his family, will also

Roxro Pharma obtained FDA approval for Sprix (ketorolac tromethamine) nasal spray in May of 2010, for the short-term (up to 5 days) management of acute moderate to moderately

NKTR-102, a novel investigational topoisomerase I inhibitor-polymer conjugate, is Nektar’s lead oncology candidate and is being evaluated in multiple cancer indications. The randomised Phase 2 study evaluated two

The double-blind, randomised, placebo-controlled Phase I will enroll up to 72 healthy adult volunteers and is designed to evaluate the safety, tolerability and pharmacokinetics of single-ascending doses of

MorphoSys claims that Sloning’s Slonomics technology enables the precise construction of protein libraries comprising defined mixtures of amino acids at pre- determined positions with unprecedented speed. The MorphoSys

Treakisym is the first anticancer agent for Eisai to launch in Japan, and although it is already available in the US. Eisai claims that Treakisym is a novel

Nifedipine is a drug belonging to a class of pharmacological agents known as the calcium channel blockers that affects the amount of calcium found in the heart and